Human Papillomavirus Vaccination of Females in a Large Health Claims Database in the United States, 2006–2012

Abstract

PurposeInformation on vaccine utilization from a variety of sources is useful to give a status of the vaccine program and define opportunities to improve uptake. We evaluated MarketScan Commercial Claims and Encounters database on human papillomavirus (HPV) vaccine initiation and completion of all three doses among girls/women from 2006 to 2012. MethodsData were obtained from the 2006–2012 MarketScan Commercial Claims and Encounters database. The study population included female enrollees aged 11–26 years who were continuously enrolled in the same private insurance plan from 2006 to 2012 (n = 407,371). We evaluated overall and yearly vaccine initiation and completion, demographic characteristics associated with vaccine initiation, clinical visits in which vaccine was given, and missed opportunities for vaccination. ResultsBy the end of 2012, 36.9% of females aged 11–26 years had received at least one HPV vaccine dose. Vaccination coverage was highest among females aged 17–18 years (49.3%) and aged 15–16 years (43.1%) and lowest among females aged 11–12 years (16.8%). Between 2007 and 2012, 96.1% of the 246,192 unvaccinated females had at least one missed opportunity (a heath care visit without HPV vaccine administered). ConclusionsOver a 6 year period, HPV vaccine initiation was lowest in the girls aged 11–12 years. Importantly, most (96.1%) unvaccinated females had at least one missed vaccination opportunity, and providers and health systems should focus efforts on using existing visits for vaccination.